Holen Sie sich die Stockscreener-App
24.62
1.03%
0.25
Handel nachbörslich:
24.62
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences inks expansion at Nova Place - Yahoo Finance
After the close on May 6, Castle Biosciences will break down Q1 - Stock Titan
Castle Biosciences inks expansion at Nova Place on North SidePittsburgh Business Times - The Business Journals
Aug EndMonth: How sensitive is Castle Biosciences Inc to inflationShare Buyback & AI Enhanced Trading Signals - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Shares Down 7%What's Next? - MarketBeat
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year - Bitget
Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal
Castle Biosciences CEO sells shares worth $246,195 By Investing.com - Investing.com Australia
Breakouts Watch: Does Castle Biosciences Inc have declining or rising EPSEarnings Miss & Fast Gain Swing Alerts - baoquankhu1.vn
Ideas Watch: Can Castle Biosciences Inc deliver alphaWeekly Trade Report & AI Forecasted Stock Moves - baoquankhu1.vn
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock - MarketBeat
Castle Biosciences CEO sells shares worth $246,195 - Investing.com
Castle Biosciences (CSTL) CEO pre-planned sale of 9,836 shares after option exercise - Stock Titan
Strong 2025 revenue and governance focus in Castle Biosciences (CSTL) proxy - Stock Titan
Castle Biosciences, Inc. (CSTL) stock price, news, quote and history - Yahoo Finance Singapore
Castle Biosciences, Inc. (CSTL) Stock Price, News, Quote & History - Yahoo! Finance Canada
AI Stocks: Can Castle Biosciences Inc maintain its current growth rate2026 Highlights & Daily Price Action Insights - baoquankhu1.vn
How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) - Yahoo Finance
CSTL PE Ratio & Valuation, Is CSTL Overvalued - Intellectia AI
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Castle Biosciences CEO Maetzold sells shares worth $106,598 By Investing.com - Investing.com South Africa
Castle Biosciences CEO Maetzold sells shares worth $106,598 - Investing.com
Castle Biosciences (CSTL) CEO executes 10b5-1 share sales, exercises options - Stock Titan
Director at Castle Biosciences (CSTL) acquires 5,329 shares via RSUs - Stock Titan
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL) - Seeking Alpha
Castle Biosciences presents melanoma test data at AAD meeting By Investing.com - Investing.com Australia
Castle Biosciences Study Shows DecisionDx-Melanoma Test Enhances Risk Prediction Within AJCC Staging System - geneonline.com
Castle Biosciences presents melanoma test data at AAD meeting - investing.com
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Newswise
Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Bitget
Derek Maetzold reports multiple Rule 144 sales — CSTL (CSTL) - Stock Titan
Vanguard realigns reporting; holds 0% of Castle Biosciences (CSTL) - Stock Titan
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Hedge Fund Moves: Can Castle Biosciences Inc deliver alpha2026 Top Decliners & High Return Trade Opportunity Guides - baoquankhu1.vn
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk - MarketBeat
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE StudySlideshow (NASDAQ:CSTL) 2026-03-23 - Seeking Alpha
Castle Biosciences Inc DecisionDx-Melanoma Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Valuation Update: Whats next for Castle Biosciences Inc stock2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Breakout Watch: Can Castle Biosciences Inc maintain its current growth rateMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
What are the future prospects of Castle Biosciences IncWeekly Stock Report & Risk Controlled Daily Plans - baoquankhu1.vn
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets - Yahoo Finance
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock By Investing.com - Investing.com India
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock - Investing.com
Derek Maetzold Sells 650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 18,650 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CEO sells 19,300 shares under 10b5-1 plan - Stock Titan
Castle Biosciences introduces 487-gene panel to guide JAK inhibitor or Th2 therapy decisions - Traders Union
1.41%
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):